Benign Acute Pericarditis: Brief Versus Longer Treatment Using Aspirin
Status:
Terminated
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
Treatment of pericarditis largely remains empirical due to the relative lack of randomized
controlled trials. Nevertheless, some recommendations have been formulated to guide
management and follow-up of acute pericarditis. Aspirin or an NSAID at medium to high dosages
is the mainstay of treatment. Optimal length of treatment is not established.
PERICARDITE is a French multicentric placebo controlled double blind randomized trial
assessing efficacy of a brief treatment based on Aspirin (4 days) versus a longer treatment
(21days) in treating a first episode of probably idiopathic acute pericarditis. It is a non
inferiority trial.
Exclusion criteria are: diseases known to cause pericarditis: (recent myocardial infarction,
autoimmune disease, postpericardiotomy syndromes, connective tissue disease, tuberculosis,
neoplastic disease).
Primary endpoint is: 30 days recovery defined as the normalization of all clinical and
paraclinical initial abnormalities.
Secondary endpoint is: 6-month recurrence.